Kairos Pharma (NYSEAMERICAN:KAPA) Earns Buy Rating from D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reiterated by D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $9.00 price target on the stock. D. Boral Capital’s target price suggests a potential upside of 476.92% from the stock’s current price.

Kairos Pharma Stock Performance

Shares of KAPA stock opened at $1.56 on Wednesday. Kairos Pharma has a 1 year low of $0.85 and a 1 year high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.